Related references
Note: Only part of the references are listed.Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2022)
Heterogeneity in COVID-19 pandemic-induced lifestyle stressors predicts future mental health in adults and children in the US and UK
Aki Nikolaidis et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2022)
Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart-Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Examining changes in personality following shamanic ceremonial use of ayahuasca
Brandon Weiss et al.
SCIENTIFIC REPORTS (2021)
The Coronavirus Health and Impact Survey (CRISIS) reveals reproducible correlates of pandemic-related mood states across the Atlantic
Aki Nikolaidis et al.
SCIENTIFIC REPORTS (2021)
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial
Alan K. Davis et al.
JAMA PSYCHIATRY (2021)
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
H. Kettner et al.
FRONTIERS IN PHARMACOLOGY (2021)
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
David E. Olson
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
David B. Yaden et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study
Qingqing Liu et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2020)
Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies
Lee E. Dunlap et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bagging improves reproducibility of functional parcellation of the human brain
Aki Nikolaidis et al.
NEUROIMAGE (2020)
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
Simon B. Goldberg et al.
PSYCHIATRY RESEARCH (2020)
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
Albert Garcia-Romeu et al.
FRONTIERS IN PSYCHIATRY (2020)
Deep learning in mental health outcome research: a scoping review
Chang Su et al.
TRANSLATIONAL PSYCHIATRY (2020)
Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
Nathan D. Sepeda et al.
JOURNAL OF PSYCHEDELIC STUDIES (2020)
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
Rafael L. Lancelotta et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2020)
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Alan K. Davis et al.
JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE (2020)
Machine learning in mental health: a scoping review of methods and applications
Adrian B. R. Shatte et al.
PSYCHOLOGICAL MEDICINE (2019)
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Alan K. Davis et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2019)
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Leor Roseman et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
A Machine Learning Approach for Studying the Comorbidities of Complex Diagnoses
Marina Sanchez-Rico et al.
BEHAVIORAL SCIENCES (2019)
Effects of psilocybin therapy on personality structure
D. Erritzoe et al.
ACTA PSYCHIATRICA SCANDINAVICA (2018)
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Alan K. Davis et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Elena Argento et al.
BMJ OPEN (2017)
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Theresa M. Carbonaro et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
A comparison of machine learning methods for classification using simulation with multiple real data examples from mental health studies
Mizanur Khondoker et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Measuring Change in Quality of Life: Bias in Prospective and Retrospective Evaluation
Christine Blome et al.
VALUE IN HEALTH (2015)
A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression
Arif Khan et al.
PLOS ONE (2012)
The inclusion of 'then-test' questions in post-test questionnaires alters post-test responses: a randomized study of bias in health program evaluation
Sandra Nolte et al.
QUALITY OF LIFE RESEARCH (2012)
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
Katherine A. MacLean et al.
JOURNAL FOR THE SCIENTIFIC STUDY OF RELIGION (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress
Lakshmi N. Ravindran et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
R. R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Response, partial response, and nonresponse in primary care treatment of depression
PK Corey-Lisle et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Share Paper
